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Abstract
In vivo pathological manifestations of eight monoclonal anti-mouse red blood cell (MRBC)
autoantibodies obtained from unmanipulated NZB mice were determined in BALB/c mice. Three
(two lgG1 and one lgG2a) of four IgG monoclonal antibodies (mAb) and two of four IgM mAb
were able to induce anemia following their i.p. injection. All five pathogenic anti-MRBC mAbs
reacted only with MRBC, whereas non-pathogenic anti-MRBC mAbs showed binding to different
species of RBC. Competition studies suggested the presence of at least two distinct epitopes
recognized by our pathogenic anti-MRBC mAb. Histological examinations revealed that anemia
resulted from either marked sequestration of agglutinated MRBC in spleens and livers or
erythrophagocytosis, most remarkably by Kupffer cells in livers. This difference was correlated
with the ability of each mAb to mediate Fc receptor-dependent phagocytosis by macrophages.
The absence of complement-mediated hemolysis in vitro and the development of anemia in
C5-deficient or C3-depleted mice indicated a minor role, if any, for complement-mediated lysis in
the anemia induced by our anti-MRBC mAb. Our results suggest that (i) at least two different
pathogenic epitopes are implicated in autoimmune hemolytic anemia; and (ii) sequestration of
agglutinated MRBC in spleens and livers and Fc receptor-dependent phagocytosis, but not
complement-mediated hemolysis, are the major mechanisms for the development of autoimmune
hemolytic anemia.
Introduction
NZB mice spontaneously develop autoimmune hemolytic anemia
as a result of production of Coombs antibodies reacting with their
own red blood cells (1). Although the molecular nature of these
autoantigens responsible for the induction of autoimmune
responses has not been well characterized, it has been shown
that there exist two major groups of anti-mouse red blood cells
(MRBC) autoantibodies: one is predominantly of the IgG class
and reacts with an exposed surface determinant of intact MRBC,
referred to as antigen 'X', and the other predominantly of the
IgM class reacting with an antigenic determinant, designated HB,
that is exposed only after treatment of MRBC with proteolytic
enzymes such as bromelin (2,3). Clearly, anti-MRBC auto-
antibodies specific for 'X' antigen are of primary significance in
the development of autoimmune hemolytic anemia of NZB mice.
In addition to their specificities, the Ig heavy chain class of
anti-MRBC autoantibodies apparently plays a significant role in
the pathogenesis of anemia by determining different effector
functions, such as complement-dependent hemolysis, Fc
receptor-mediated phagocytosis, and multivalency-induced
hemagglutination (4).
Development of several monoclonal antibodies (mAb) reacting
with intact MRBC, derived from unimmunized or rat RBC-
immunized NZB mice, has been reported previously (5-8).
Intraperitoneal implantation of hybridoma cells secreting IgM
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anti-MRBC mAb could induce anemia, as documented by a
decrease in hematocrits (Ht) (6-8). However, some hybridoma
cells secreting anti-MRBC mAb failed to induce significant anemia
(6), and the implantation of non-anti-RBC hybridoma cells could
cause anemia as a result of i.p. hemorrhage due to their vascular
invasion. Therefore, the interpretation for the development of
anemia following the i.p. injection of hybridoma cells should be
cautious. In the present study we have assessed the in vivo
pathogenic activity of eight anti-MRBC mAb, obtained from
unmanipulated anemic NZB mice, by a single i.p. injection of
purified mAb and determined their pathogenic mechanisms in
relation to the specificities and effector functions of anti-MRBC
mAb. Our results indicate that five of eight mAb were able to
cause anemia within a few days due to either Fc receptor-
mediated erythrophagocytosis or marked sequestration of
agglutinatated MRBC in spleens and livers, and that at least two
distinct species-specific antigens of MRBC were involved in the
pathogenesis of autoimmune hemolytic anemia.
Methods
Mice
NZB, BALB/c, and DBA/2 mice were purchased from Gl.
Bomholtgart Ltd, Ry, Denmark. Mice were bled from the retro-
orbital plexus and the resulting sera were stored at -20°C.
Anti-MRBC and other mAb
Hybridomas used in this study were derived from four different
fusions of spleen cells from unmanipulated adult anemic NZB
mice with the myeloma cell lines, NS-2 or X63-Ag8.653.
Anti-MRBC autoantibody activities in hybridoma supernatants
were detected by an indirect radioimmunoassay (RIA) as
described below. Positive hybridomas were cloned by limiting
dilution. Hybridoma cells were maintained in Dulbecco's modified
Eagle's medium (DMEM) supplemented with additional amino
acids (9), 10 mM HEPES, 5 x 10"5 M 2-mercaptoethanol, and
10% FCS. Isotypes of anti-MRBC mAb and their concentrations
were determined by Ig class-specific enzyme-linked immuno-
sorbent assays (ELISA) as described previously (10). IgM
anti-bromelinized MRBC (CP3.23-24) mAb (11), IgM (41-5C)
mAb derived from NZB mice, and lgG1, lgG2a, and lgG2b
anti-dinitrophenyl mAb (12) were used as controls. Rat anti-mouse
IgG Fc receptor mAb (2.4G2) was kindly provided by Dr J. C.
Unkeless, Mount Sinai School of Medicine, New York (13).
Purification, concentration, and iodination of antibodies
IgG mAb were purified from culture supernatants using a
staphylococcal protein A column (Pharmacia Fine Chemicals,
Uppsala, Sweden). IgM mAb were purified by euglobulin
precipitation from either ascites or culture supernatants con-
centrated by 50% saturated ammonium sulphate precipitation,
according to the method of Garcfa-Gonzales et al. (14). The
purity of IgG and IgM mAb was >90% as documented by
SDS - PAGE. For some in vivo experiments, culture supernatants
were concentrated x 10 by 50% saturated ammonium sulphate
precipitation. Polyclonal mouse IgG was prepared from pooled
normal mouse serum on a protein A affinity column. Purified
polyclonal and mAb were labeled with 125I by the chloramin T
method (15).
Indirect anti-MRBC assay
An indirect RIA was used to detect anti-MRBC activities in culture
supernatants or sera. One hundred microliters of hybridoma
culture supernatants or 1:1000 diluted sera were incubated
with 10/J of 25% MRBC suspension freshly prepared from
BALB/c mice overnight at 4°C, room temperature, or 37°C.
After washing three times with PBS, the MRBC were incubated
overnight at 4°C with 100 /xl of '25I-Iabeled rabbit anti-mouse
Ig (DAKOPATTS, Copenhagen, Denmark) or 125l-labeled rat
anti-mouse /i chain-specific mAb (LO-MM-9; a kind gift of Dr H.
Bazin, Belgium) (16) in 1 % BSA - PBS. After washing with PBS,
the radioactivity bound to MRBC was counted in a 7-counter.
Results are expressed as the percentage of [125l]anti-mouse
Ig bound to MRBC. This indirect RIA was also used for the
determination of anti-MRBC mAb binding to different species
(human, sheep, chick, rabbit, and rat) of RBC. Sheep RBC and
chick RBC were purchased from Behringwerke AG, Marburg,
FRG, and Flow Laboratories, Allschwil, Switzerland, respectively.
Competitive inhibition assay
Fifty nanograms of 125l-labeled anti-MRBC mAb diluted in 50 /*l
of 1 % BSA - PBS were mixed with 50 p\ of various amounts of
different unlabeled mAb, followed by the addition of 50 /tl of 0.2%
MRBC suspension. After an overnight incubation at 4°C, the
mixtures were washed three times with PBS and the radioactivity
bound to MRBC was counted. Results are expressed as the
percentage inhibition of [125l]anti-MRBC mAb binding to MRBC.
Direct anti-MRBC assay
In vivo bound anti-MRBC mAb were detected by a direct
anti-MRBC RIA. Fifty microliters of blood samples were collected
into heparinized tubes containing 1 ml of PBS. After washing four
times, 50 /tl of 2.5% MRBC suspension in 1 % BSA- PBS were
incubated with 50 /tl of either [125l]rabbit anti-mouse Ig or
[125l]rat anti-mouse /i chain-specific mAb (LO-MM-9) at 4°C.
After washing three times, the radioactivity bound to MRBC was
counted by a 7-counter. Results are expressed as the percentage
of [125l]anti-mouse Ig bound to MRBC.
Determination of Ht
Blood samples were collected into heparinized microhematocrit
tubes (Clay Adams, Parsippany, NY) and centrifuged at 12,000
r.p.m. for 5 min in a microfuge (Sigma-201 M, Auer Bittmann
Soulie AG, Geneva, Switzerland). Percentage of packed RBC
volume was directly measured after centrifugation.
Histopathology
Major organs including spleens and livers were obtained at
autopsy, processed for histological examination, and stained with
hematoxylin and eosin (HE).
In vivo depletion of C3
To deplete C3, BALB/c mice received three i.v. injections of Naja
naja cobra venom factor (CVF, Diamedix Corp., Miami, FL): 7.5 U
CVF 8 h before the injection of anti-MRBC mAb and 2.5 U CVF
1 and 2 days after the anti-MRBC mAb injection. This treatment
decreased serum levels of C3 to - 5 % of control values, as
determined by radial immunodiffusion.
Complement-mediated lysis
Fifty microliters of 0.25, 0.5, or 1 % MRBC suspension were
incubated with 100 pi of various concentrations (0.1 -100 fig/ml)
of anti-MRBC or control mAb at room temperature for 60 min
in round-bottom microtiter plates (Sterilin Ltd, Feltham, UK). After
washing with Hanks' medium, 50 ^l of 10% guinea pig, rabbit
(Cedarlane Laboratories, Ltd, Ontario, Canada), or fresh mouse
serum were added as a source of complement. The suspensions
were incubated at 37°C for 30 min, then hemolysis was
determined macroscopically.
Opsonization of MRBC with anti-MRBC mAb
Five hundred microliters of packed MRBC freshly prepared
from BALB/c mice were incubated with 50 nQ of purified mAb
in 10 ml of 1% BSA-PBS. After incubation for 30 min at room
temperature, and washing with PBS, a 50% suspension of
opsonized MRBC in PBS was prepared.
In vitro Fc receptor-mediated phagocytosis
Peritoneal cells were collected from unmanipulated BALB/c mice
and suspended in DM EM. Peritoneal cells (3 x 105) were then
allowed to adhere to Falcon 6-well plates by 1 h incubation at
37°C. Following washing, adherent cells, which consisted of
- 9 9 % macrophages as revealed by Giemsa staining, were
further incubated at 37°C overnight in a humidified incubator
containing 5% CO2 in air. One hundred microliters of
50% opsonized MRBC suspension were added to adherent
macrophages and incubated at 37°C for 1 h. After extensive
washings with Hanks' medium, plates were treated with distilled
water for 10 s to lyse extracellular MRBC. Isotonicity was quickly
restored by adding Hanks' medium.
Hemagglutination assay
A one-step hemagglutination assay was performed as follows.
Fifty microliters of serial dilutions of culture supernatants were
mixed with 50 pi of 0.5% MRBC suspension in 1% BSA-PBS
in round-bottom microtiter plates and incubated at room
temperature for 1 h. In each experiment, control IgG and
IgM mAb or 1% BSA-PBS were used as negative controls.
Hemagglutination titers are expressed as the reciprocal of the
final dilution, giving a positive macroscopic hemagglutination.
Results
In vitro binding activity of anti-MRBC mAb to RBC
Eight hybridomas secreting IgM (1E10, 4C8, 103-7E, and
106-10E), lgG1 (31-9D and 105-2H), lgG2b (34-2B), or lgG2a
(34-3C) anti-MRBC mAb were prepared from four separate
fusions with spleen cells of anemic NZB mice. All eight mAb
exhibited significantly increased binding activities to intact MRBC
at 4°C compared with control mAb and polyclonal mouse IgG
(Table 1). Essentially identical activities were observed at room
temperature and at 37°C except for the 4C8 and 103-7E mAb,
which showed slightly higher binding activity at 4°C (35.2 and
23.6%) than at room temperature (21.6 and 13.4%) or 37°C (21.2
and 12.4o/o).
When the binding of these anti-MRBC mAb with RBC from five
different species (rat, sheep, rabbit, chick, and human) was
examined, three different groups of anti-MRBC mAb were
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Table 1 . In vitro binding of anti-MRBC mAb to different species
of RBC
mAba
1E10 (ji, x)
4C8 Gt, x)
31-9D(71, x)
105-2H ( 71, x)
34-3C (72a, x)
34-2B (72b, x)
103-7E (11, x)
106-10E (/t,x)
Mouse
40.7
45.5
18.4
20.2
21.0
13.6
57.9
44.1
Rat
0.3
1.7
0.6
0.7
0.5
8.4
59.0
39.3
Sheep
0.9
2.6
1.0
1.9
1.0
1.2
64.2
22.0
Rabbit
0.7
0.8
0.8
1.3
1.7
1.0
49.8
25.6
Chick
0.5
0.7
0.6
0.7
1.0
0.8
71.3
38.7
Human
0.2
0.8
0.3
0.9
0.4
1.2
22.5
32.4
a2 fig of each mAb were incubated with RBC from different species
overnight at 4°C. Results are expressed as percentage of 125l-labeled
anti-mouse Ig bound to RBC. Background binding activities obtained by
control IgM and IgG mAb or by polyclonal mouse IgG from a pooled
normal mouse serum were <2°/o.
identified (Table 1). The first group, consisting of 1E10, 4C8,
31-9D, 105-2H, and 34-3C mAb, reacted with only MRBC. The
second group (34-2B mAb) exhibited binding activity with both
mouse and rat RBC. The third group (103-7E and 106-10E)
reacted with the RBC of all species tested.
To further define the specificity of the first group of anti-MRBC
mAb, 34-3C, 1E10, or 4C8 mAb was iodinated and the
competitive inhibition assay was performed in the presence of
excess amounts of different mAb. As shown in Fig. 1, not only
the 34-3C mAb but also the 105-2H mAb were able to inhibit
almost completely the MRBC-binding by the [125I]34-3C mAb.
However, the inhibitory activity of 34-3C mAb was ~25-fold
stronger than that of 105-2H mAb. A slight inhibition (15%) by
200-fold excess of 1E10 or 4C8 mAb was observed, and no
inhibition by other anti-MRBC mAb (31-9D, 34-2B, 103-7E, and
106-10E). When the competition assay was performed with
[125I]1E1O mAb, 34-3C mAb exhibited the highest inhibitory
activity (Fig. 1). In fact, 80 ng of 34-3C mAb completely inhibited
the binding of 50 ng of [12s|]1E10 mAb, while only 50% inhibi-
tion was achieved by the same amount of 1E10 mAb. The 4C8
and 105-2H mAb exhibited similar inhibitory activity to that of the
1E10 mAb: all three mAb at a dose of 2 pg completely inhibited
the MRBC-binding of [l25|]1E10 mAb. Partial inhibition was
observed by 103-7E and 31-9D mAb at 40- to 200-fold excess,
and no inhibition by 34-2B and 106-10E mAb. When [125|]4C8
mAb was used for the competition assay, results were essentially
identical to those obtained with [125I]1E1O mAb (data not
shown). These results suggested that 1E10, 4C8, 105-2H, and
34-3C mAb may recognize the same antigen—different from that
recognized by the 31-9D mAb—and, if so, the affinity of the 34-3C
mAb is far higher than that of the others.
Induction of anemia by the injection of anti-MRBC mAb
Since eight anti-MRBC mAb exhibited substantial binding activity
to intact MRBC in vitro at 37°C as well as at 4°C, the
pathogenicity of anti-MRBC mAb was investigated by a single
i.p. injection of purified mAb in BALB/c mice. The injection of
100 HQ of purified mAb of two IgM (1E10 and 4C8), lgG1 31-9D,
or lgG2a 34-3C mAb caused a rapid decrease in Ht values, and
1E10 mAb even killed all animals within 1 or 2 days after its
injection (Fig. 2). In contrast, lgG1 105-2H, lgG2b 34-2B, and
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Fig. 1 . Inhibitory activities of various amounts of unlabeled anti-MRBC
mAb(O,34-3C; • , 105-2H; A, 1E10; A, 31-9D; O, 4C8; • , 103-7E;
o , 34-2B; • , 106-10E) on the MRBC-binding by 50 ng of p25|]34-3C
or [125I]1E1O anti-MRBC mAb. Results are expressed as percentage
inhibition of [125I]34-3C or p25|]iE10 mAb-binding to MRBC.
two IgM (103-7E and 106-10E) mAb were not able to significantly
decrease Ht values.
To compare the pathogenic activity of the anti-MRBC mAb
quantitatively, various amounts of mAb were injected and the
quantities of mAb required to induce anemia (decreasing Ht
values to <4O°/o), to cause a 50% decrease in Ht values
(decreasing Ht values to <24%), and to kill animals were
estimated. The 31-9D mAb exhibited the strongest activity for
inducing anemia (Table 2). In fact, only 5/tg of mAb were
sufficient to induce anemia; Ht values dropped from 50 to 34%
4 days after the injection. This dose was 5 -10 times less than
that of the other three highly pathogenic mAb (34-3C, 1E10, and
4C8). Similar differences were observed when compared with
the amount of mAb required for a 50% decrease in Ht values.
However, the 1E10 mAb was most toxic, because only 100 ng
were sufficient to kill mice, while 2 .5-5 times more mAb was
required for 31-9D, 4C8, and 34-3C mAb. Although 100 ^g of
105-2H mAb failed to induce anemia, anemia was observed at
IgM anti-MRBC mAb
*
IgG anti-MRBC mAb
0 1 2 3 4 5 6 7
Days after Injection of Anti-MRBC mAb
Fig. 2. Development of anemia in BALB/c mice after a single i.p.
injection of 100 pg of purified IgM anti-MRBC mAb (upper panel: A, 1E10;
A.4C8; O, 103-7E; • , 106-10E) or IgG anti-MRBC mAb (lower panel:
A, 31-9D; A, 105-2H; O, 34-3C; • , 34-2B). Results are mean Ht values
of five mice. Note that all the mice injected with 1E10 mAb died within
2 days after injection.
Table 2. Estimation of quantities of mAb required for inducing
anemia and killing mice
mAb
1E10
4C8
31-9D
105-2H
34-2C
Dose required for
inducing anemiaa
kg)
25
50
5
250
50
Dose required for
50% decrease in Htb
kg)
75
200
15
1200
100
Lethal dose
kg)
100
250
250
NDC
500
aThe quantity of mAb required for inducing anemia. Ht values <40%
(= <3 SD from mean values of 3- to 4-month-old BALB/c mice) were
considered as anemic.
bThe quantity of mAb required for causing a 50% decrease in Ht
values (Ht values decreased to <24%).
cNot determined.
Table 3. In vivo MRBC binding by pathogenic but not
non-pathogenic anti-MRBC mAb
mAb
1E10
4C8
31-9D
105-2H
34-3C
103-7E
106-10E
34-2B
Ht
17
20
16
20
21
46
44
43
(%
±
±
±
±
±
±
±
±
)
2
8
3
2
5
3
2
2
mAb
17.2
23.4
9.6
10.3
9.4
0.7
0.6
1.9
bound to MRBCa
±
±
±
±
±
±
±
±
3.3
5.9
0.9
0.8
0.8
0.2
0.3
0.2
Free anti-MRBCb
1.2
0.5
1.1
1.0
1.3
22.2
27.5
8.0
a 5 -10 days after injection of 5 x 106 hybridoma cells, the amount
of mAb bound to MRBC in vivo was determined by direct RIA. Results
are expressed as percentage binding of |125l]anti-mouse Ig on MRBC
(mean of 4 - 8 mice ± 1 SD). Background binding activities obtained
in mice injected with control hybridomas were <2%.
bFree anti-MRBC activities in 1/1000 diluted sera pooled from 4 - 8
mice were determined by indirect RIA. Results are expressed as
percentage binding of [125l]anti-mouse Ig bound to MRBC. Background
binding activities in sera from mice injected with control hybridomas were
a dose of 250 ^g, which was 50 times higher than that of 31-9D
mAb of the same Ig subclass, and 1.2 mg was required to cause
a 50% decrease in Ht values. Notably, no anemia developed
following the injection of ascites containing 10 mg of lgG2b
34-2B, IgM (103-7E and 106-10E) anti-MRBC mAb, or control
mAb of any IgG subclass or IgM, including anti-bromelinized
MRBC mAb.
Lack of in vivo MRBC binding by non-pathogenic anti-MRBC
mAb
Since experiments of anti-MRBC mAb injection have shown that
three of eight anti-MRBC mAb failed to induce anemia, we
examined whether these mAb were able to bind MRBC in vivo.
In mice developing anemia 5 -10 days after the injection of five
different hybridoma cells, significant amounts of antibodies bound
to MRBC were detectable in all cases, while there was no
demonstrable activity of free anti-MRBC antibodies in their sera
(Table 3). In contrast, none of the mice transplanted with three
non-pathogenic anti-MRBC hybridomas had MRBC bound with
anti-MRBC antibodies at a significant level, although substantial
activity of unbound anti-MRBC antibodies was found in their sera.
Histopathological manifestations induced by the injection of
anti-MRBC mAb
Histological examinations revealed two different pathological
changes, depending on the mAb, in spleens and livers of the
mice which had either died of acute anemia or developed a
severe anemia after the injection of mAb. The first group of mAb,
i.e. two IgM (1E10 and 4C8) and lgG1 (31-9D) mAb at a dose
of 100 - 250 IIQ, induced a marked splenomegaly associated with
an enormous accumulation of agglutinated RBC in the spleen,
which prevented recognition of splenic architecture (Fig. 3A). In
the liver agglutinated RBC were accumulated in sinusoids,
causing marked necrosis of hepatic parenchymal cells (Fig. 3B).
However, erythrophagocytosis by Kupffer cells or by splenic
macrophages was barely detectable. In contrast, in mice
administered by the second group of mAb, 500 ng of lgG2a
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(34-3C) or 2 mg of IgGi (105-2H), erythrophagocytosis by Kupffer
cells was the most remarkable pathological change (Fig. 3C and
D). Notably, no significant histological alterations were observed
in mice injected with ascites containing 10 mg of three other
anti-MRBC mAb (34-2B, 103-7E, and 106-10E) or control mAb
(Fig. 3E and F).
Induction of anemia in C5-deficient or C3-depleted mice by
anti-MRBC mAb
To determine the role of complement-mediated lysis in anemia
induced by MRBC mAb, 100 ng of 4C8 (IgM), 31-9D (lgG1), or
34-3C (lgG2a) were injected i.p. into C5-deficient DBA/2 mice
(17), and CVF-treated or control BALB/c mice. The extent and
kinetics of anemia induced by these mAb in DBA/2 mice were
essentially identical to those in BALB/c mice (Table 4). CVF-
treated BALB/c mice similarly developed anemia, although their
anemia was more severe than that of the control group of mice.
This was probably caused by the effect of CVF alone, since
CVF-treated mice receiving control non-anti-MRBC mAb exhibited
a slight decrease in Ht values. It should be noted that, when
MRBC opsonized with these mAb were subjected to complement-
mediated lysis in vitro in the presence of guinea pig, rabbit,
or mouse serum, no macroscopically visible hemolysis was
observed (data not shown).
Fc receptor-mediated phagocytosis and hemagglutination of
MRBC opsonized with anti-MRBC mAb
Because none of the mAb capable of inducing anemia caused
complement-mediated hemolysis in vitro, and because both
C5-deficient and C3-depleted mice developed anemia, the
observed difference in pathological manifestations may be related
to a difference in the ability of the anti-MRBC mAb to bind
the FC7 receptors of macrophages and/or to induce hemag-
glutination. As shown in Fig. 4, MRBC opsonized with 31-9D,
4C8, or 1E10 mAb were not significantly phagocytosed by
peritoneal macrophages. In contrast, remarkably high and
moderate levels of phagocytosis were observed when MRBC
were opsonized with lgG2a 34-3C and lgG1 105-2H mAb,
respectively. Notably, this phagocytosis was completely inhibited
in the presence of a rat anti-murine Fc> receptor mAb (2.4G2)
(data not shown). Finally, it was found that an i.v. administration
of 1 mg of 2.4G2 mAb 2 h before the anti-MRBC mAb injection
completely inhibited the development of anemia induced by
lgG2a 34-3C mAb, but did not inhibit at all that induced by lgG1
31-9D or IgM 4C8 mAb (Table 5).
When the hemagglutination activity was determined in vitro,
both 1E10 and 4C8 IgM mAb markedly agglutinated MRBC
(hemagglutination titers of culture supernatants: 1E10,1024; 4C8,
4096). However, none of the other anti-MRBC mAb, including
two non-pathogenic IgM anti-MRBC (103-7E and 106-10E) mAb,
agglutinated the MRBC, although they reacted well with MRBC
under this condition, as determined by RIA.
Discussion
The present study represents an extensive analysis of the
pathological manifestations of eight monoclonal anti-MRBC
autoantibodies obtained from unimmunized NZB mice. Although
all eight anti-MRBC mAb reacted well with MRBC in vitro at 37°C
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Fig. 3. (A and 3) Representative histological appearance of spleen and liver trom bALb/c mice wnicn aiea or anemia z aays arter tne injection
of 100 ^g of 1E10 anti-MRBC mAb. Note an enormous accumulation of agglutinated RBC in the entire spleen, rendering the splenic architecture
hardly recognizable (A; HE, x 24), and marked necrosis of hepatic parenchymal cells secondary to the accumulation of agglutinated RBC in sinusoids
of liver (B; HE, x24). Essentially identical lesions were observed in mice injected with 31-9D or 4C8 mAb. (C and D) Representative histological
appearance of spleen and liver from BALB/c mice which died of anemia 4 days after the injection of 500 ^g of 34-3C anti-MRBC mAb. Note the
absence of accumulation of agglutinated RBC in spleen (C; HE, x 24) and liver (D; HE, x 240) but remarkable erythrophagocytosis by Kupffer cells
in liver (D). Similar histological changes were observed in mice developing anemia after the injection of 2 mg of 105-2H mAb. (E and F) Represen-
tative histological appearance of spleen and liver in mice injected with 10 mg of 34-2B anti-MRBC mAb. Note that there are no significant histological
alterations in spleen (E; HE, x24) and liver (F; HE, x24). Mice injected with either 103-7E or 106-10E mAb exhibited no appreciable changes in
spleens and livers (not shown).
as well as at 4°C, only five of them were able to bind MRBC
in vivo, causing anemia either by Fc receptor-mediated
erythrophagocytosis or by marked sequestration of agglutinated
MRBC in spleens and livers, but not by complement-mediated
hemolysis. The distinct difference in the specificity between
pathogenic and non-pathogenic anti-MRBC mAb strongly
Table 4. Development of anemia in C5-deficient DBA/2 and
CVF-treated BALB/c mice after injection of anti-MRBC mAb
mAb
4C8
31-9D
34-3C
41-5C"
DBA/2
36 ± 3a
20 ± 1
26 ± 2
47 ± 2
BALB/c
CVF
28 ± 3a
ND
19 ± 2
41 ± 1
Control
35 ± 3a
17 ± 1
24 ± 1
47 ± 1
aHt values (mean of 5 mice ± 1 SD) were determined 3 days after
i.p. injection of 100 HQ of anti-MRBC mAb. CVF were injected i.v. 8 h
before and 1 and 2 days after the anti-MRBC mAb injection. Note that
serum levels of C3 at the time of anti-MRBC mAb injection were - 5 %
of control values, which remained until day 3. ND, not done.
blgM non-anti-MRBC mAb.
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suggests the importance of autoantibody specificity for the
pathogenesis of autoimmune hemolytic anemia.
It is significant that all five pathogenic autoantibodies recognize
only species-specific antigens (at least two distinct epitopes) on
MRBC, while non-pathogenic antibodies recognize cross-reactive
determinants present only on rat RBC or on RBC from many
species such as human, sheep, rabbit, and chick. In this regard,
it should be mentioned that one IgM anti-MRBC mAb (G-8),
established by Caulfield etal. (8) and whose pathogenic activity
was demonstrated by the transplantation of hybridoma cells, also
reacts specifically with MRBC. These results are consistent
with earlier findings that autoantibodies eluted from RBC of
Coombs-positive NZB mice react only with MRBC but not with
human, rat, sheep, guinea pig, or rabbit RBC (2,18). Thus, at
least two species-specific epitopes, as suggested by the present
competition experiment, are likely to be involved in the
pathogenesis of autoimmune hemolytic anemia. Clearly, the
identification of the biochemical nature of pathogenic epitopes
is of importance to understand the immunopathogenesis of
autoimmune hemolytic anemia.
The importance of the specificity of anti-MRBC mAb in
the pathogenesis of autoimmune hemolytic anemia is best
documented by the finding that among four IgM anti-MRBC mAb
Fig. 4. In vitro phagocytosis by peritoneal macrophages of MRBC opsonized with either 34-3C (A), 105-2H (B), 31-9D (C), or 4C8 (D) anti-MRBC
mAb. Note the marked and moderate phagocytosis of MRBC opsonized with 34-3C and 105-2H mAb, respectively, but the absence of significant
phagocytosis of MRBC opsonized with either 31-9D or 4C8 mAb. No phagocytosis was observed with MRBC coated with 1E10 anti-MRBC mAb
(not shown).
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Table 5. Effect of anti-Fc7 receptor mAb (2.4G2) on the
development of anti-MRBC mAb-induced anemia
mAb
34-3C
31-9D
4C8
Day 0
47 ±
49 ±
49 ±
1b
1
1
Day 3
2.4G2a
46 ± 1 b
24 ± 3
32 ± 3
Control
21 ± 3b
26 ± 2
35 ± 1
a1 mg of anti-Fc7 receptor mAb (2.4G2) was given i.v. 2 h before the
injection of anti-MRBC mAb.
bHt values (mean of 5 mice ± 1 SD) were determined 3 days after
i.p. injection of 100 /ig of anti-MRBC mAb.
only two (1E10 and 4C8) are able to induce anemia. The marked
in vitro and in vivo hemagglutination by pathogenic 1E10 and
4C8 mAb but not by non-pathogenic 103-7E and 106-10E mAb
can be explained by the difference in specificity of these
two groups of mAb. It may be that the density of antigenic
determinant recognized by 1E10 and 4C8 mAb is much higher
than that recognized by 103-7E and 106-10E mAb. Alternatively,
the antigen recognized by 1E10 and 4C8 mAb may be distributed
in small clusters on MRBC, as recently demonstrated for
the complement receptor type 1 on human RBC (19). Such
differences in the distribution of target antigens could also account
for the difference in in vivo binding to MRBC by these two groups
of anti-MRBC mAb.
The present finding that none of the anti-MRBC mAb, even
IgM mAb, are able to lyse MRBC in vitro in the presence of
complement from mice, rabbits or guinea pigs may not be totally
surprising. In fact, non-complement-fixing IgM antibodies with
diverse specificities have been described in various species,
including mouse (20-23). Since the structure of the antigen
appears to influence the capacity of IgM antibodies to fix and/or
activate complement (24,25), the failure of hemolysis by our
autoantibodies may be related to the particular structure of the
target RBC antigen. This notion was further supported by a recent
observation that some lymphocyte surface antigens are better
targets for complement-mediated lysis than others, independent
of their densities (26). Thus, it may be possible that the antigens
involved in anti-MRBC autoimmune responses and bound by
anti-MRBC mAb could not efficiently activate C1, probably
because of their low mobility in the RBC membrane. Whatever
the reason, the development of anemia in C5-deficient DBA/2
mice as well as normal BALB/c mice clearly indicates a
minor role, if any, of complement-mediated hemolysis in the
pathogenesis of anemia induced by our anti-MRBC mAb. In this
regard, it should be noted that NZB mice are congenially
deficient in hemolytic complement activity (27) yet develop severe
autoimmune hemolytic anemia. Finally, the complete prevention
of anemia induced by the lgG2a 34-3C mAb by the injection of
anti-Fc? receptor mAb and the similar development of anemia
in both C3-depleted and control mice argue against the possible
involvement of C3 receptor-mediated erythrophagocytosis in
the development of anemia induced by our anti-MRBC mAb.
Notably, our results do not exclude the possibility that
combinations of antibodies against different epitopes might lead
to complement-mediated hemolysis.
Our in vitro and in vivo results combined with histological
examinations have clearly shown that two different mechanisms
are responsible for the development of anemia induced by our
anti-MRBC mAb. In the case of lgG2a 34-3C and lgG1 105-2H
anti-MRBC mAb, which bind efficiently to Fc receptors on
macrophages, the major cause of anemia is apparently a rapid
Fc receptor-mediated phagocytosis of opsonized MRBC, most
remarkably by Kupffer cells. In contrast, with the two IgM (1E10
and 4C8) and lgG1 31-9D anti-MRBC mAb which fail to mediate
Fc receptor-dependent phagocytosis, anemia is most likely
caused by the marked sequestration of agglutinated RBC in
spleen and liver. Subsequent liver damage and hemodynamic
failure are likely to be additional contributing factors to the animals'
death, explaining why this group of mAb was more toxic than
the first group of pathogenic mAb. It should be mentioned that
both 31-9D and 105-2H mAb are of the lgG1 class, yet a
substantial difference exists in their ability to mediate Fc
receptor-dependent phagocytosis. Since both mAb recognize
different epitopes, limited phagocytosis of MRBC opsonized with
the 31-9D mAb may be due to the difference in the distribution
and nature of antigenic determinants recognized by each mAb.
Although the specificity of autoantibodies is important, it is
apparent that other factors may determine the pathogenic activity
of anti-MRBC mAb. The best example is the difference in the
pathogenic potential between lgG2a 34-3C and lgG1 105-2H
mAb. Although both mAb appear to recognize the same epitope,
the competition experiment strongly suggested that the affinity
of 34-3C mAb to MRBC is far higher than that of 105-2H mAb.
In addition, in vitro experiments on Fc receptor-mediated
phagocytosis have shown that lgG2a 34-3C mAb exhibits greater
binding to Fc receptor than does lgG1 105-2H mAb, owing to
the difference in the affinity of the Fc receptor for lgG2a and of
the Fc receptor for lgG1/lgG2b (28,29). Both differences in the
affinities of mAb for the target antigen and for the Fc receptor
may well explain the fact that the pathogenic activity of lgG2a
34-3C mAb is ~ 10 times stronger than that of lgG1 105-2H mAb.
Our present studies have demonstrated several important
points: (i) not all the autoantibodies reactive with intact MRBC
in vitro are able to induce anemia; (ii) all five pathogenic
autoantibodies recognize antigenic determinants expressed only
on MRBC but not on other species of RBC, suggesting the
importance of the specificity of anti-MRBC autoantibodies;
and (iii) the affinities of autoantibodies for the target antigens and
for the Fey receptors of macrophages, and the ability to
cause hemagglutination are additional factors determining the
pathogenic activity of anti-MRBC autoantibodies. Although it is
obvious that the anti-MRBC mAb studied here may not represent
the full range of pathogenic anti-MRBC autoantibodies occurring
in the NZB mouse, the substantial variation of pathogenic activities
observed among anti-MRBC mAb could explain the remarkable
individual variability in the progression of autoimmune hemolytic
anemia in the NZB mouse. Since recent structural analysis of
autoantibodies has revealed the oligoclonal origin of autoimmune
responses (30), the selection of different autoreactive clones
during the early course of autoimmune responses may markedly
influence the onset and progression of autoimmune hemolytic
anemia in the NZB mouse. Finally, the development of the
experimental model of autoimmune hemolytic anemia described
here certainly represents a good opportunity to evaluate various
therapeutic approaches based on interference at the level of the
essential pathogenic pathways.
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